United Therapeutics Corporation (NASDAQ:UTHR - Get Free Report) CEO Martine Rothblatt sold 9,500 shares of the company's stock in a transaction that occurred on Friday, October 23rd. The stock was sold at an average price of $582.76, for a total transaction of $5,536,220.00. Following the completion of the transaction, the chief executive officer owned 324,443 shares in the company, valued at approximately $189,072,402.68. This represents a 2.84% decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through this hyperlink.
United Therapeutics Price Performance
Shares of NASDAQ:UTHR opened at $592.84 on Tuesday. United Therapeutics Corporation has a 1 year low of $409.07 and a 1 year high of $609.35. The stock's fifty day moving average price is $521.24 and its 200-day moving average price is $528.49. The company has a market cap of $25.43 billion, a P/E ratio of 21.21, a PEG ratio of 4.26 and a beta of 0.49.
United Therapeutics (NASDAQ:UTHR - Get Free Report) last released its quarterly earnings results on Wednesday, August 5th. The biotechnology company reported $7.27 earnings per share for the quarter, beating the consensus estimate of $6.86 by $0.41. United Therapeutics had a return on equity of 20.18% and a net margin of 41.56%. The firm had revenue of $783.30 million for the quarter, compared to analysts' expectations of $804.65 million. During the same period in the prior year, the firm earned $6.41 EPS. The company's revenue was down 1.9% compared to the same quarter last year. On average, sell-side analysts anticipate that United Therapeutics Corporation will post 26.07 earnings per share for the current year.
United Therapeutics declared that its board has authorized a share buyback plan on Thursday, October 22nd that authorizes the company to buy back $2 billion in shares. This buyback authorization authorizes the biotechnology company to buy up to 8.3% of its stock through open market purchases. Share buyback plans are typically a sign that the company's board believes its stock is undervalued.
Analyst Upgrades and Downgrades
Several research firms have recently commented on UTHR. Morgan Stanley boosted their target price on shares of United Therapeutics from $515.00 to $566.00 and gave the stock an "equal weight" rating in a report on Wednesday, October 7th. Royal Bank Of Canada dropped their price objective on shares of United Therapeutics from $708.00 to $697.00 and set an "outperform" rating for the company in a research note on Thursday. Bank of America lowered their price target on shares of United Therapeutics from $620.00 to $613.00 and set a "neutral" rating for the company in a report on Friday, July 10th. Weiss Ratings lowered United Therapeutics from a "buy (b)" rating to a "buy (b-)" rating in a report on Thursday, August 27th. Finally, JPMorgan Chase & Co. lifted their price target on shares of United Therapeutics from $685.00 to $687.00 and gave the stock an "overweight" rating in a research note on Thursday, July 23rd. Twelve equities research analysts have rated the stock with a Buy rating, two have given a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and an average price target of $666.50.
View Our Latest Stock Report on United Therapeutics
Institutional Investors Weigh In On United Therapeutics
A number of hedge funds and other institutional investors have recently added to or reduced their stakes in UTHR. BlackRock Inc. purchased a new position in United Therapeutics in the 2nd quarter worth $2,868,735,000. Janus Henderson Group PLC raised its stake in shares of United Therapeutics by 8.9% during the 1st quarter. Janus Henderson Group PLC now owns 866,930 shares of the biotechnology company's stock worth $514,016,000 after buying an additional 70,829 shares during the period. Jupiter Topco LLC purchased a new position in United Therapeutics during the second quarter valued at $450,140,000. Swedbank AB lifted its position in shares of United Therapeutics by 0.7% in the first quarter. Swedbank AB now owns 327,122 shares of the biotechnology company's stock valued at $193,977,000 after acquiring an additional 2,350 shares in the last quarter. Finally, Pictet Asset Management Holding SA boosted its stake in United Therapeutics by 0.8% during the 1st quarter. Pictet Asset Management Holding SA now owns 309,220 shares of the biotechnology company's stock worth $183,306,000 after purchasing an additional 2,383 shares during the last quarter. 94.08% of the stock is currently owned by hedge funds and other institutional investors.
About United Therapeutics
(
Get Free Report)
United Therapeutics Corporation is a biotechnology company focused on developing and commercializing therapies for patients with life-threatening conditions, particularly pulmonary arterial hypertension (PAH). The company's portfolio includes Tyvaso and Tyvaso DPI, inhaled formulations of treprostinil; Remodulin, an injectable treprostinil product; and Orenitram, an oral treprostinil therapy. These treatments are designed to improve exercise ability and delay disease progression in people with PAH.
The company also markets Unituxin, an antibody therapy used as part of treatment for high-risk neuroblastoma, a type of childhood cancer.
See Also
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
